GlaxoSmithKline’s Collection of Bribery Allegations Multiplies
British drug maker GlaxoSmithKline (NYSE:GSK) is facing another criminal investigation, this time in Poland. The news comes after previous reports of similar bribery allegations in Iraq. Last year, the company came under fire for corruption charges at its Chinese unit as, well. The resulting investigation into the Chinese bribery charges has resulted in significant sales losses in that country for the company.
According to a report from BBC News published Sunday, 11 doctors and one GSK regional manager are facing corruption charges for actions undertaken between 2010 and 2012 in Poland.
An ex-employee of the pharmaceutical giant says that doctors were paid bribes to recommend GlaxoSmithKline’s asthma drug, Seretide, over competing brands. The company said that it is cooperating with the investigation and that one employee has already been disciplined.
“Following receipt of allegations regarding the conduct of the programme in the Lodz region, GSK has investigated the matter, using resources from both inside and outside the company. The investigation found evidence of inappropriate communication in contravention of GSK policy by a single employee. The employee concerned was reprimanded and disciplined as a result,” a GSK statement said, per BBC News.
The statement continued: “We continue to investigate these matters and are cooperating fully with the CBA [Poland's Central Anticorruption Office].”